CA2365040A1 - Compositions hob-bp2h, leurs techniques et leurs utilisations - Google Patents

Compositions hob-bp2h, leurs techniques et leurs utilisations Download PDF

Info

Publication number
CA2365040A1
CA2365040A1 CA002365040A CA2365040A CA2365040A1 CA 2365040 A1 CA2365040 A1 CA 2365040A1 CA 002365040 A CA002365040 A CA 002365040A CA 2365040 A CA2365040 A CA 2365040A CA 2365040 A1 CA2365040 A1 CA 2365040A1
Authority
CA
Canada
Prior art keywords
polypeptide
hob
bp2h
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002365040A
Other languages
English (en)
Inventor
Eric Wen Su
Jian-Jun Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2365040A1 publication Critical patent/CA2365040A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne au moins un nouveau polypeptide hOB-BP2h, comprenant des acides nucl~iques isol~s qui codent au moins pour un polypeptide hOB-BP2h, des polypeptides hOB-BP2h, des vecteurs, des cellules hÙtes, des organismes transg~niques et chim~riques, ainsi que des techniques de pr~paration et d'utilisation de ces compositions, et des techniques et des anticorps sp~cifiques de hOB-BP2h.
CA002365040A 1999-04-02 2000-03-22 Compositions hob-bp2h, leurs techniques et leurs utilisations Abandoned CA2365040A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12766799P 1999-04-02 1999-04-02
US60/127,667 1999-04-02
PCT/US2000/006682 WO2000059942A2 (fr) 1999-04-02 2000-03-22 COMPOSITIONS hOB-BP2h, LEURS TECHNIQUES ET LEURS UTILISATIONS

Publications (1)

Publication Number Publication Date
CA2365040A1 true CA2365040A1 (fr) 2000-10-12

Family

ID=22431287

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002365040A Abandoned CA2365040A1 (fr) 1999-04-02 2000-03-22 Compositions hob-bp2h, leurs techniques et leurs utilisations

Country Status (5)

Country Link
EP (1) EP1169350A2 (fr)
JP (1) JP2003500016A (fr)
AU (1) AU3883800A (fr)
CA (1) CA2365040A1 (fr)
WO (1) WO2000059942A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153542A0 (en) * 2000-07-21 2003-07-06 Bristol Myers Squibb Co SIALIC ACID BINDING Ig-RELATED LECTIN PROTEINS
US7202056B2 (en) 2002-03-28 2007-04-10 Bristol-Myers Squibb Company Polynucleotides encoding a human cell surface protein with immunoglobulin folds, BGS-19
ATE500842T1 (de) 2002-05-04 2011-03-15 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
MX348062B (es) 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
EP1928490B8 (fr) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions et procedes d'utilisation de mutants des chondroitinases abci
WO2007081608A2 (fr) * 2005-11-21 2007-07-19 Genentech, Inc. Nouvelles dissociations de gènes, compositions et procédés les concernant
AU2007307736C1 (en) 2006-10-10 2014-04-10 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
JPH10286089A (ja) * 1997-04-15 1998-10-27 Otsuka Pharmaceut Co Ltd ヒト遺伝子
EP0983078A4 (fr) * 1997-05-27 2003-03-26 Smithkline Beecham Corp Adnc de la famille des sialoadhesines 4 (saf-4)

Also Published As

Publication number Publication date
AU3883800A (en) 2000-10-23
JP2003500016A (ja) 2003-01-07
WO2000059942A2 (fr) 2000-10-12
EP1169350A2 (fr) 2002-01-09
WO2000059942A3 (fr) 2001-07-05

Similar Documents

Publication Publication Date Title
AU744875B2 (en) Prostate tumor polynucleotide and antigen compositions
JP3492999B2 (ja) 脂肪細胞特異的タンパク質の同族体
EP0904278A1 (fr) Molecule ii inductrice d'apoptose
JP2002500043A (ja) アポトーシス誘導分子ii
CA2365040A1 (fr) Compositions hob-bp2h, leurs techniques et leurs utilisations
JPH10150993A (ja) 新規g−蛋白結合受容体hltex11
WO1998011136A1 (fr) ADNc ET PEPTIDE LIES AU CANCER ET A LA PERTE DE POIDS
WO2000015781A1 (fr) Antagonistes du facteur de croissance des fibroblastes
JP2002508166A (ja) ヒトDendriacおよびBrainiac−3
US7195902B2 (en) Phosphatases which activate map kinase pathways
WO1998053069A2 (fr) Recepteurs du gdnf
US20030211991A1 (en) Human sez6 nucleic acids and polypeptides
CA2341688A1 (fr) Acides nucleiques d'homologue du facteur 8, polypeptides, procedes et utilisations
WO2000005248A1 (fr) Cellules hotes, vecteurs, polypeptides, acides nucleiques de gdf-3 humains et leur methodes d'utilisation
WO2000012117A1 (fr) ACIDES NUCLEIQUES, POLYPEPTIDES HOMOLOGUES DE Wnt, PROCEDES ET UTILISATIONS
WO2000006714A1 (fr) ACIDES NUCLEIQUES DDKh-3, POLYPEPTIDES, VECTEURS, CELLULES HOTES, PROCEDES ET UTILISATIONS
WO2002002771A2 (fr) Nouveau gene hsparc-11 et procedes de fabrication et d'utilisation de ce dernier
US20030120039A1 (en) Human preoptic regulatory factor-2 and uses thereof
WO2000037492A2 (fr) ACIDES NUCLEIQUES huHDGFH, POLYPEPTIDES, PROCEDES ET UTILISATIONS DE CEUX-CI
WO2001042464A2 (fr) Facteur 2 de regulation preoptique humain et ses utilisations
EP1290026A2 (fr) Acides nucleiques et polypeptides sez6 humains
WO2001000662A2 (fr) Utilisation de polypeptides fgh-8 humains comme agents neurotrophiques
JP2000106889A (ja) 分泌マウスタンパク質sFRP―1に類似した新規ヒト遺伝子
WO2000006591A2 (fr) Acide nucleique adap, polypeptides, vecteurs, cellules hotes, techniques et utilisations
WO2001066738A2 (fr) Acides nucleiques codant des polypeptides crsp1 humains et utilisations de ces derniers

Legal Events

Date Code Title Description
FZDE Dead